Seres Therapeutics Inc Forecast, price target & analysts
Seres Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Seres Therapeutics Inc Classifications & Recommendation:
Seres Therapeutics Inc Price Target
| Target Price | $21.42 |
| Price | $15.30 |
| Potential |
40.00%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Seres Therapeutics Inc 2026 .
The average Seres Therapeutics Inc target price is $21.42.
This is
40.00%
register free of charge
$23.10
50.98%
register free of charge
$20.20
32.03%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Seres Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2026 of
40.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 0.27 |
5 Analysts have issued a sales forecast Seres Therapeutics Inc 2025 . The average Seres Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $0.0 | |
|---|---|---|
| 2026 |
$0.0
100.00%
Unlock
|
|
3 Analysts have issued an Seres Therapeutics Inc EBITDA forecast 2025. The average Seres Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
5 Seres Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Seres Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.01 | 0.72 |
| 100.06% | 7,100.00% | |
| P/E | 21.13 | |
| EV/Sales | 333.71 |
5 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Seres Therapeutics Inc stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 259.35 | 91.50% |
|---|---|---|
| 2025 |
333.71
28.67%
Unlock
|
|
P/S ratio
| Current | 395.46 | 84.82% |
|---|---|---|
| 2025 |
508.85
28.67%
Unlock
|
|
Seres Therapeutics Inc...
Current Seres Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 14 2024 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
